TaiGen Entered into an Exclusive License Agreement with Joincare to Develop and Commercialize TG-1000 in China
Shots:
- TaiGen to receive $2.90M & milestones followed by ~11% of royalties. Joincare will lead the development, registration & commercialization of TG-1000 in the territory incl. China, Hong Kong & Macao by undertaking all costs of clinical trials
- Reduced virus load and pharmacokinetics in flu-infected animals and patients show excellent performance in both pre-clinical & clinical trial data with TG-1000 treatment. The P-II study results showed that TG-1000 effectively alleviates flu symptoms & clear flu viruses
- The novel pan-influenza antiviral TG-1000 is effective against influenza A, influenza B, avian flu H7N9 & Tamiflu-resistant viruses by preventing viral replication & transmission through a cap-snatching mechanism
Ref: PRNewswire / Image: TaiGen
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
